N/A
N=105
Pancreatic Juice Diagnosis From Duodenum
Pancreatic Adenocarcinoma
Bottom Line
View on ClinicalTrials.gov: NCT01699698 ↗Enrolled (actual)
105
Serious AEs
0.0%
Results posted
Sep 2015
Primary outcome: Primary: The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort — 99097; 34095 pg/ml — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Tumor markers (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Olympus Corporation
- Primary completion
- Jul 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Concentration of the Pancreatic Cancer Markers of the Normal Cohort and UICC Stage II Pancreatic Ductal Adenocarcinoma Cohort |
99097; 34095 | <0.001 sig |
| SECONDARY The Sensitivity and Specificity to Detect UICC Stage II Pancreatic Ductal Adenocarcinoma Among All Participants. |
31; 17 | — |
Summary
Purpose of this study is to understand the clinical feasibility of duodenal juice diagnosis to screen UICC stage II pancreatic ductal adenocarcinoma patients.
Eligibility Criteria
Inclusion Criteria
- Common inclusion criterion
- Age is 18 years or older.
- Informed consent was obtained.
- Inclusion criterion for normal cohort
- An upper GI endoscopy is scheduled to check upper abdominal symptoms.
- No findings of pancreatic disorder as documented by CT or MRI or EUS
- Inclusion criterion for PC suspicious cohort
- A EUS or ERCP is scheduled to suspected pancreatic disorder.
Exclusion Criteria
- Common exclusion criterion
- Severe cardiac disease
- Severe respiratory disease
- Bleeding disorders
- Pregnancy
Data sourced from ClinicalTrials.gov (NCT01699698). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.